VolitionRX (VNRX) Stock Price, News & Analysis

Company Overview

VolitionRx Limited is a biotechnology company developing blood-based diagnostic tests intended to support the early detection and management of disease. Its technology platform, Nu.Q, analyzes nucleosomes—small structures released into the bloodstream when cells die—to identify biological signals associated with cancer and other conditions.

The company’s products and development programs serve human and veterinary health markets. Its Nu.Q Vet platform is designed to help veterinarians screen for and monitor cancer in companion animals, while the company is also developing Nu.Q-based applications for human cancer, infectious diseases, and other medical conditions. VolitionRx has pursued commercial distribution through partners and veterinary diagnostic channels.

VolitionRx was established in 2010 and has conducted research and development activities in Europe, the United States, and other international markets. The company is led by Cameron Reynolds, who serves as president and group chief executive officer. Its operations include research, assay development, regulatory efforts, and commercialization of Nu.Q-based diagnostic products.

Key Stats

• Today's Range: $0.19 to $0.24
• 50-Day Range: $0.17 to $0.35
• 52-Week Range: $0.16 to $7.73
• Volume: 53.28 million shs
• Average Volume: 3.07 million shs
• Market Capitalization: $3.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.00
• Consensus Rating: Hold

VolitionRX Stock Analysis - MarketRank™

VolitionRX scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

VolitionRX has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 2 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

VolitionRX has a consensus price target of $28.00, representing about 13,297.1% upside from its current price of $0.21.

Amount of Analyst Coverage

VolitionRX has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of VolitionRX is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of VolitionRX is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.99% of the float of VolitionRX has been sold short.

Short Interest Ratio / Days to Cover

VolitionRX has a short interest ratio ("days to cover") of 1.19, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in VolitionRX has recently increased by 21.91%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

VolitionRX does not currently pay a dividend.

Dividend Growth

VolitionRX does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.92

News Sentiment

VolitionRX has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for VolitionRX this week, compared to 2 articles on an average week.

MarketBeat Follows

11 people have added VolitionRX to their MarketBeat watchlist in the last 30 days. This is an increase of 267% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, VolitionRX insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.90% of the stock of VolitionRX is held by insiders.

Percentage Held by Institutions

8.09% of the stock of VolitionRX is held by institutions.

Company Calendar

• Last Earnings: 11/12/2026
• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:VNRX
• Previous Symbol: NYSEMKT:VNRX
• CIK: 93314
• Web: www.volition.com
• Phone: (646) 650-1351
• Fax: 65 32 8172 5651
• Employees: 75
• Year Founded: N/A

Price Target and Rating

• Average Price Target for VolitionRX: $28.00
• High Price Target: $60.00
• Low Price Target: $4.00
• Potential Upside/Downside: +12,289.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.36 million
• Net Margins: -1,043.12%
• Pretax Margin: -1,046.83%
• Return on Equity: N/A
• Return on Assets: -303.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.30
• Quick Ratio: 0.30

Sales & Book Value

• Annual Sales: $1.73 million
• Price / Sales: 1.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($5.30) per share
• Price / Book: -0.04

Miscellaneous

• Outstanding Shares: 13,650,000
• Free Float: 12,707,000
• Market Cap: $3.08 million
• Optionable: Not Optionable
• Beta: 1.16